IL327041A - Methods, compositions and kits comprising cell-penetrating agents - Google Patents

Methods, compositions and kits comprising cell-penetrating agents

Info

Publication number
IL327041A
IL327041A IL327041A IL32704126A IL327041A IL 327041 A IL327041 A IL 327041A IL 327041 A IL327041 A IL 327041A IL 32704126 A IL32704126 A IL 32704126A IL 327041 A IL327041 A IL 327041A
Authority
IL
Israel
Prior art keywords
cmip
cell
amino acid
salt
acid residue
Prior art date
Application number
IL327041A
Other languages
English (en)
Hebrew (he)
Inventor
Tarlochan S Nijjar
Stephen Jed Tam
Original Assignee
Prothena Platform Tech Limited
Tarlochan S Nijjar
Stephen Jed Tam
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Prothena Platform Tech Limited, Tarlochan S Nijjar, Stephen Jed Tam filed Critical Prothena Platform Tech Limited
Publication of IL327041A publication Critical patent/IL327041A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/43504—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
    • C07K14/43513—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from arachnidae
    • C07K14/43518—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from arachnidae from spiders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/10—Fusion polypeptide containing a localisation/targetting motif containing a tag for extracellular membrane crossing, e.g. TAT or VP22

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Insects & Arthropods (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Cell Separators (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Battery Mounting, Suspending (AREA)
IL327041A 2023-09-15 2024-09-13 Methods, compositions and kits comprising cell-penetrating agents IL327041A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202363538596P 2023-09-15 2023-09-15
PCT/US2024/046659 WO2025059491A2 (en) 2023-09-15 2024-09-13 Methods, compositions, and kits including cell-penetrating agents

Publications (1)

Publication Number Publication Date
IL327041A true IL327041A (en) 2026-05-01

Family

ID=92966495

Family Applications (1)

Application Number Title Priority Date Filing Date
IL327041A IL327041A (en) 2023-09-15 2024-09-13 Methods, compositions and kits comprising cell-penetrating agents

Country Status (10)

Country Link
EP (1) EP4777522A2 (de)
KR (1) KR20260074695A (de)
CN (1) CN122029182A (de)
AR (1) AR133830A1 (de)
AU (1) AU2024342899A1 (de)
IL (1) IL327041A (de)
PY (1) PY2480771A (de)
TW (1) TW202528337A (de)
UY (1) UY40891A (de)
WO (1) WO2025059491A2 (de)

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0279582A3 (de) 1987-02-17 1989-10-18 Pharming B.V. DNA-Sequenzen die Proteine zwecks effizienter Abscheidung zur Milchdrüse leiten
US5633076A (en) 1989-12-01 1997-05-27 Pharming Bv Method of producing a transgenic bovine or transgenic bovine embryo
AU6014094A (en) 1992-12-02 1994-06-22 Baylor College Of Medicine Episomal vectors for gene therapy
US5827690A (en) 1993-12-20 1998-10-27 Genzyme Transgenics Corporatiion Transgenic production of antibodies in milk
US5505947A (en) 1994-05-27 1996-04-09 The University Of North Carolina At Chapel Hill Attenuating mutations in Venezuelan Equine Encephalitis virus
US5786464C1 (en) 1994-09-19 2012-04-24 Gen Hospital Corp Overexpression of mammalian and viral proteins
US7153510B1 (en) 1995-05-04 2006-12-26 Yale University Recombinant vesiculoviruses and their uses
DE19539493A1 (de) 1995-10-24 1997-04-30 Thomae Gmbh Dr K Starker homologer Promotor aus Hamster
US6114148C1 (en) 1996-09-20 2012-05-01 Gen Hospital Corp High level expression of proteins
US5888809A (en) 1997-05-01 1999-03-30 Icos Corporation Hamster EF-1α transcriptional regulatory DNA
PE20020574A1 (es) 2000-12-06 2002-07-02 Wyeth Corp Anticuerpos humanizados que reconocen el peptido amiloideo beta
DE50308030D1 (de) 2002-11-29 2007-10-04 Boehringer Ingelheim Pharma Neue neomycin-phosphotransferase-gene und verfahren zur selektion von hochproduzierenden rekombinanten zellen
DE10338531A1 (de) 2003-08-19 2005-04-07 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Reklonierung von Produktionszellen
EP1820022B1 (de) 2004-11-10 2009-06-03 Boehringer Ingelheim Pharma GmbH & Co. KG Verwendung von durchflusszytometrischer analyse zur optimierung von zellbankingstrategien für cho-zellen
US20080124760A1 (en) 2006-07-26 2008-05-29 Barbara Enenkel Regulatory Nucleic Acid Elements
EP2522730A1 (de) 2007-03-02 2012-11-14 Boehringer Ingelheim Pharma GmbH & Co. KG Verbesserung der Herstellung von Proteinen
EP2031064A1 (de) 2007-08-29 2009-03-04 Boehringer Ingelheim Pharma GmbH & Co. KG Verfahren zur Steigerung von Proteintitern
GB201916884D0 (en) * 2019-11-20 2020-01-01 Evox Therapeutics Ltd Nanoparticle-like delivery system
AU2021339003A1 (en) 2020-09-10 2023-02-09 Ludwig-Maximilians-Universität München Engineered AAV vectors

Also Published As

Publication number Publication date
EP4777522A2 (de) 2026-07-22
AR133830A1 (es) 2025-11-05
PY2480771A (es) 2025-05-12
UY40891A (es) 2025-02-28
CN122029182A (zh) 2026-05-12
WO2025059491A3 (en) 2025-05-15
KR20260074695A (ko) 2026-05-26
WO2025059491A2 (en) 2025-03-20
AU2024342899A1 (en) 2026-04-23
TW202528337A (zh) 2025-07-16

Similar Documents

Publication Publication Date Title
EP4329879A4 (de) N,n-dimethyltryptamin-zusammensetzungen und verfahren
EP4247376A4 (de) Verbindungen, zusammensetzungen und verfahren
ZA202200652B (en) Compositions, kits, methods and uses for preventing microbial growth
IL317671A (en) History of anilinopyrazole, its preparations and methods
EP4370110A4 (de) Verbindungen, zusammensetzungen und verfahren
AU2020298782B2 (en) Combination therapy methods, compositions and kits
EP4041856A4 (de) Verfahren und zusammensetzungen zur verminderung von geruch und biofilm
WO2022170008A3 (en) Anti-il1rap antibodies
IL315948A (en) Compounds, preparations and methods
GB2621686B (en) Compositions, and methods and uses relating thereto
IL326943A (en) Compounds, compositions and methods
CA3304787A1 (en) Methods, compositions, and kits including cell-penetrating agents
EP4267198A4 (de) Gallengangfreisetzungsverfahren, zusammensetzungen und kits zur verwendung darin
IL320161A (en) Compounds, compositions and methods
GB202014256D0 (en) Treatments, related compositions and kits
GB202112817D0 (en) Methods, compositions, and kits for characterizing skins
EP4323442A4 (de) Verfahren und zusammensetzungen zur verringerung der autofluoreszenz
GB202302117D0 (en) Compositions, kits and combinations
GB202302118D0 (en) Compositions, kits and combinations
AU2020407501A1 (en) Methods and compositions for evaluating and treating fibrosis
HK40074329A (en) Combination therapy methods, compositions and kits
GB202213022D0 (en) Compositions, and methods and uses relating thereto
GB202209297D0 (en) Compositions, and methods and uses relating thereto
GB202405929D0 (en) Compositions, uses and methods
CA3273729A1 (en) Compositions, methods and uses